Standard

Effect of mildronate on quality of life of patients with chronic heart failure. / Nedoshivin, A. O.; Petrova, N. N.; Kutuzova, A. E.; Perepech, N. V.

в: Terapevticheskii Arkhiv, Том 71, № 8, 1999, стр. 10-12.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Nedoshivin, AO, Petrova, NN, Kutuzova, AE & Perepech, NV 1999, 'Effect of mildronate on quality of life of patients with chronic heart failure', Terapevticheskii Arkhiv, Том. 71, № 8, стр. 10-12.

APA

Nedoshivin, A. O., Petrova, N. N., Kutuzova, A. E., & Perepech, N. V. (1999). Effect of mildronate on quality of life of patients with chronic heart failure. Terapevticheskii Arkhiv, 71(8), 10-12.

Vancouver

Nedoshivin AO, Petrova NN, Kutuzova AE, Perepech NV. Effect of mildronate on quality of life of patients with chronic heart failure. Terapevticheskii Arkhiv. 1999;71(8):10-12.

Author

Nedoshivin, A. O. ; Petrova, N. N. ; Kutuzova, A. E. ; Perepech, N. V. / Effect of mildronate on quality of life of patients with chronic heart failure. в: Terapevticheskii Arkhiv. 1999 ; Том 71, № 8. стр. 10-12.

BibTeX

@article{e45acb7e91184ee9a24b2c2248c04ef4,
title = "Effect of mildronate on quality of life of patients with chronic heart failure",
abstract = "Aim. To study quality of life (QL) of patients with chronic heart failure (CHF) and QL changes resultant from mildronate therapy. Materials and methods. QL was studied in 30 IHD patients with CHF of NYHA class II-IV, ejection fraction > 45%; 40 IHD patients without CHF and 30 healthy subjects. CHF patients were treated for 30 days with oral mildronate (250mg 4 times a day). QL was assessed according to the method SF-36 Health Status Survey. Results. QL in CHF patients is much lower than that of the controls. Objective severity of the disease and subjective satisfaction with life do not always coincide. Mildronate in a dose 1 g/day per os may be beneficial for LQ of CHF patients. Conclusion. It is thought desirable to include QL in analysis of efficiency of managing parents with CHF. SF-36 is a tool able to follow up changes in QL of CHF patients within a short-term treatment period.",
keywords = "Chronic heart failure, Mildronate, Quality of life, SF-36",
author = "Nedoshivin, {A. O.} and Petrova, {N. N.} and Kutuzova, {A. E.} and Perepech, {N. V.}",
year = "1999",
language = "English",
volume = "71",
pages = "10--12",
journal = "ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)",
issn = "0040-3660",
publisher = "Медицина",
number = "8",

}

RIS

TY - JOUR

T1 - Effect of mildronate on quality of life of patients with chronic heart failure

AU - Nedoshivin, A. O.

AU - Petrova, N. N.

AU - Kutuzova, A. E.

AU - Perepech, N. V.

PY - 1999

Y1 - 1999

N2 - Aim. To study quality of life (QL) of patients with chronic heart failure (CHF) and QL changes resultant from mildronate therapy. Materials and methods. QL was studied in 30 IHD patients with CHF of NYHA class II-IV, ejection fraction > 45%; 40 IHD patients without CHF and 30 healthy subjects. CHF patients were treated for 30 days with oral mildronate (250mg 4 times a day). QL was assessed according to the method SF-36 Health Status Survey. Results. QL in CHF patients is much lower than that of the controls. Objective severity of the disease and subjective satisfaction with life do not always coincide. Mildronate in a dose 1 g/day per os may be beneficial for LQ of CHF patients. Conclusion. It is thought desirable to include QL in analysis of efficiency of managing parents with CHF. SF-36 is a tool able to follow up changes in QL of CHF patients within a short-term treatment period.

AB - Aim. To study quality of life (QL) of patients with chronic heart failure (CHF) and QL changes resultant from mildronate therapy. Materials and methods. QL was studied in 30 IHD patients with CHF of NYHA class II-IV, ejection fraction > 45%; 40 IHD patients without CHF and 30 healthy subjects. CHF patients were treated for 30 days with oral mildronate (250mg 4 times a day). QL was assessed according to the method SF-36 Health Status Survey. Results. QL in CHF patients is much lower than that of the controls. Objective severity of the disease and subjective satisfaction with life do not always coincide. Mildronate in a dose 1 g/day per os may be beneficial for LQ of CHF patients. Conclusion. It is thought desirable to include QL in analysis of efficiency of managing parents with CHF. SF-36 is a tool able to follow up changes in QL of CHF patients within a short-term treatment period.

KW - Chronic heart failure

KW - Mildronate

KW - Quality of life

KW - SF-36

UR - http://www.scopus.com/inward/record.url?scp=0032618293&partnerID=8YFLogxK

M3 - Article

C2 - 10515026

AN - SCOPUS:0032618293

VL - 71

SP - 10

EP - 12

JO - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)

JF - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)

SN - 0040-3660

IS - 8

ER -

ID: 86255959